ESMO2019_BANNER_NL_senza_logo_20190524_1000x190

Saturday, September 28 | 18:30- 20:00

Santander Auditorium, Hall 3, Fira Gran Via, Barcelona, Spain


Co-Chairs

Massimo Cristofanilli, MD

Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL

Wolfgang Janni, MD

University of Ulm, Germany


Faculty

Jean-Yves Pierga, MD, PhD

Institut Curie & Université Paris Descartes, France


Johann De Bono, MD, PhD

The Institute of Cancer Research and Royal Marsden, London, UK

 


OBJECTIVES

  • Review the clinical data supporting the prognostic value of CTCs enumeration in early and advanced breast cancer
  • Review the clinical data supporting the prognostic role of CTCs enumeration in advanced prostate cancer
  • Summarize current evidence and provide recommendation for CTCs enumeration use in the routine care of patients with advanced breast and prostate cancer

PROGRAMME

18:30-18:45 A single baseline CTC count for staging of metastatic Breast Cancer: beyond anatomical description – M Cristofanilli

 

18:45-19:00 Prognostic and predictive value of CTC count in the management of HR+ Metastatic Breast Cancer – JY Pierga

 

19:00-19:15  Prognostic role of CTC detection in HR+ Early Breast Cancer - W Janni

 

19:15-19:30  CTC count and single cells evaluation in metastatic  Prostate Cancer – J De Bono

 

19:30- 20:00 The current value of CTCs in patients’ management (Roundtable)